A Study to Determine the Safety, Tolerability, and Effects of GSK2374697 in Healthy Volunteers

Summary

This is a single-blinded, randomized, placebo-controlled, staggered-parallel, escalating dose study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK2374697 in healthy volunteers. The study will enrol approximately 72 subjects at one clinical study center in the United States.

Timeline

Start

2011-11-07

Primary completion

2012-12-23

Completion

2012-12-23

Publications

• Lin J, Hodge RJ, O'Connor-Semmes RL, Nunez DJ. GSK2374697, a long duration glucagon-like peptide-1 (GLP-1) receptor agonist, reduces postprandial circulating endogenous total GLP-1 and peptide YY in healthy subjects. Diabetes Obes Metab. 2015 Oct;17(10):1007-10. doi: 10.1111/dom.12533. Epub 2015 Aug 11.

Drugs

Indications